FindMyKOL

Aaron Aday, MD

Basic profile

Cardiovascular Disease

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionNashville, TN · SoutheastSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLFindMyKOL type: RegionalLatest publicationNot yet indexedOnline presenceNot yet checkedPayments2021 onwardNIH funding2020–2025Why? →

Aaron Aday is a Cardiology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials ↓
7companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2020–2025

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Novartis
    Program year20252 paymentsResearch
    $15,789
  • Merck Sharp & Dohme LLC
    Program year202517 payments
    $10,792
  • TACTILE SYSTEMS TECHNOLOGY INC
    Program year20251 payment
    $2,000
All 16 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    68.6%
    Statin26.3%
    Atorvastatin Calcium74%Rosuvastatin Calcium26%
    Part D≥24 patients
    Beta blocker14.3%
    Metoprolol Succinate59%Carvedilol41%
    Part D<11 patients

    + 5 more classes in this area

  • Blood & clotting

    31.4%
    Factor Xa inhibitor24.5%
    Xarelto56%Eliquis45%
    Part D<11 patients
    Vitamin K antagonist3.6%
    Warfarin Sodium100%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)56.2% facility · 43.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 2020–2025 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”